

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

208341Orig1s000

PHARMACOLOGY REVIEW(S)

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH**

PHARMACOLOGY/TOXICOLOGY NDA/BLA REVIEW AND EVALUATION

Application number: 208341
Supporting document/s: New/NDA 0001
Applicant's letter date: 10/28/2015
CDER stamp date: 10/28/2015
Product: Epclusa™ (SOF/VEL; 400/100 mg)
Indication: HCV, Genotype 1-6
Applicant: Gilead
Review Division: DAVP
Reviewer: John Dubinion, Ph.D.
Supervisor/Team Leader: Hanan Ghantous, Ph.D., DABT
Division Director: Debra B. Birnkrant, M.D.
Project Manager: Linda Onaga, MPH

Disclaimer

Except as specifically identified, all data and information discussed below and necessary for approval of NDA #208341 are owned by Gilead Sciences, Inc. or are data for which Gilead has obtained a written right of reference.

Any information or data necessary for approval of NDA #208341 that Gilead does not own or have a written right to reference constitutes one of the following: (1) published literature, or (2) a prior FDA finding of safety or effectiveness for a listed drug, as reflected in the drug's approved labeling. Any data or information described or referenced below from reviews or publicly available summaries of a previously approved application is for descriptive purposes only and is not relied upon for approval of NDA #208341.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY.....	7
1.1 INTRODUCTION	7
1.2 BRIEF DISCUSSION OF NONCLINICAL FINDINGS	7
1.3 RECOMMENDATIONS	8
2 DRUG INFORMATION.....	8
2.1 DRUG	8
2.1.1 SOFOSBUVIR.....	8
2.1.2 VELPATASVIR.....	9
2.2 RELEVANT INDs, NDAs, BLAs AND DMFs	10
2.3 DRUG FORMULATION	10
2.4 COMMENTS ON NOVEL EXCIPIENTS	11
2.5 COMMENTS ON IMPURITIES/DEGRADANTS OF CONCERN	11
2.6 PROPOSED CLINICAL POPULATION AND DOSING REGIMEN	11
2.7 REGULATORY BACKGROUND	11
3 STUDIES SUBMITTED.....	11
3.1 STUDIES REVIEWED FOR VEL.....	11
3.2 STUDIES NOT REVIEWED.....	14
3.3 PREVIOUS REVIEWS REFERENCED.....	15
4 PHARMACOLOGY	15
4.1 PRIMARY PHARMACOLOGY	15
4.2 SECONDARY PHARMACOLOGY	15
4.3 SAFETY PHARMACOLOGY	16
5 PHARMACOKINETICS/ADME/TOXICOKINETICS	17
5.1 PK/ADME	17
6 GENERAL TOXICOLOGY.....	32
6.1 SINGLE-DOSE TOXICITY	32
6.2 REPEAT-DOSE TOXICITY	32
7 GENETIC TOXICOLOGY.....	52
7.1 <i>IN VITRO</i> REVERSE MUTATION ASSAY IN BACTERIAL CELLS (AMES)	52
7.2 <i>IN VITRO</i> ASSAYS IN MAMMALIAN CELLS	54
7.3 <i>IN VIVO</i> CLASTOGENICITY ASSAY IN RODENT (MICRONUCLEUS ASSAY)	55
8 REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY	57
8.1 FERTILITY AND EARLY EMBRYONIC DEVELOPMENT	57
8.2 EMBRYONIC FETAL DEVELOPMENT.....	59
8.3 PRENATAL AND POSTNATAL DEVELOPMENT	67
9 SPECIAL TOXICOLOGY STUDIES	74

10 INTEGRATED SUMMARY AND SAFETY EVALUATION.....77
11 APPENDIX/ATTACHMENTS82

Table of Tables

Table 1: Quantitative Composition of Sofosbuvir/Velpatasvir Tablets	10
Table 2: Mean Pharmacokinetic Parameters of GS-5816 after a Single Oral Gavage Dose to CD-1 Male Mice	18
Table 3: Mean Pharmacokinetic Parameters of GS-5816 after a Single Oral Gavage Dose to 001178-W (wild type) Mice	18
Table 4: Pharmacokinetic Parameters of GS-5816 Following Single Ascending Oral Doses in SD Rats	19
Table 5: Pharmacokinetic Parameters of GS-5816 in SD Rats Following Single Oral Doses of GS-5816 in Differing Formulations	19
Table 6: Pharmacokinetic Parameters of GS-5816 Following Intravenous and Oral Administration of GS-5816 to Male Rats	20
Table 7: Pharmacokinetic Parameters of GS-5816 Following Single Ascending Oral Doses of GS-5816 to Beagle Dogs	20
Table 8: Pharmacokinetic Parameters of GS-5816 Following IV and Oral Doses of GS-5816 to Male Beagle Dogs	21
Table 9: Pharmacokinetic Parameters of GS-5816 Following IV and Oral Doses of GS-5816 to Male Cynomolgus Monkeys	21
Table 10: Pharmacokinetic Parameters of GS-5816 Following Single Ascending Oral Doses of GS-5816 to Female NZW Rabbits	22
Table 11: Pharmacokinetic Parameters of GS-5816 in Female NZW Rabbits Following a Single Oral Dose of GS-5816 (600 mg/kg) in Various Formulations	22
Table 12: Pharmacokinetic Parameters of GS-5816 Following Single Ascending Oral Doses of GS-5816 to Female NZW Rabbits	23
Table 13: Protein Binding of GS-5816 in CD-1 Mouse Plasma	23
Table 14: Protein Binding of GS-5816 in Human Plasma at Different GS-5816 Concentrations	24
Table 15: Protein Binding of GS-5816 in Plasma from Different Species	24
Table 16: Relative Protein Binding of GS-5816 in CCM vs. Human Plasma	25
Table 17: Pharmacokinetic Parameters for ¹⁴ C-GS-5816 in Blood and Plasma From CD-1 and rasH2 Transgenic Mice After a Single Administration	25
Table 18: Pharmacokinetic Parameters for Radioactivity in Blood, Plasma, and Milk From Lactating Rats After Single Oral Dose of ¹⁴ C-GS-5816 (30 mg/kg)	27
Table 19: Pharmacokinetic Parameters of GS-5816 Following IV Administration to Female NZW Rabbits	27
Table 20: In Vitro Rate of Metabolism of GS-5816 in Mice Hepatic Microsomes	28
Table 21: In Vitro Rate of Metabolism of GS-5816 in Cryopreserved Human Hepatocytes	28
Table 22: In Vitro Rate of Metabolism of GS-5816 in Hepatic Microsomes	29
Table 23: IC ₅₀ Values for Major Human CYP450 Enzymes for GS-5816 and Positive Control Inhibitors	32
Table 24: Toxicokinetic Parameters for GS-5816 in Rat Plasma on Day 5	33
Table 25: Toxicokinetic Parameters for GS-5816 in Rat Plasma - Day 1 and Day 14 ..	34
Table 26: Toxicokinetic Parameters for GS-5816 and GS-5816-B in Male Rat Plasma: Days 1 and 14	35

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.